Zhitong Finance App learned that on September 30, 2020, Fuhong Hanlin (02696) issued an announcement announcing the resignation of Scott Shi-Kau Liu, Dr. Liu Shigao as the company's executive director and CEO due to adjustments in his personal work focus. After his resignation, Dr. Liu Shigao will serve as the director of Fuhong Hanlin's strategic advisory committee, continuing to focus on the company's R&D direction, company strategy formulation, and team building and development. At the same time, the company nominated Mr. Zhang Wenjie, the current president, as the executive director of the second board of directors and appointed him as the CEO, who will lead the senior management team in the daily management of the company and supervise the operations of the company and its subsidiaries.
Mr. Zhang Wenjie has more than 25 years of commercial operation and management experience in the pharmaceutical industry. Since joining Fuhong Hanlin in March 2019, he has been responsible for the company's operation and management, focusing on building innovative commercial operation models, creating an international strategic layout, and successfully promoting Fuhonglin's core product, Han Qu Yu®It went public smoothly. Prior to joining Fuhong Hanlin, Mr. Zhang Wenjie served as General Manager of Amgen China, Vice President of Oncology Business Division II of Shanghai Roche Pharmaceutical Co., Ltd., and Head of China's Bayer Schilling Special Medicine and Oncology Department.
As an innovative biopharmaceutical company, Fuhong Hanlin is committed to providing high-quality and affordable innovative biopharmaceuticals to patients around the world. Its products cover the fields of tumors and autoimmune diseases. Since its establishment in 2010, thanks to the efforts of Dr. Liu Shigao and the excellent management team, Fuhong Hanlin has built an integrated biopharmaceutical platform. The independent core capabilities of efficiency and innovation run through the entire R&D, production and commercial operation industry chain. At the same time, a diversified, high-quality product pipeline has been forward-looking, covering more than 20 innovative monoclonal antibodies. The company successfully launched Hanlikon® (rituximab), the first biosimilar in China, and Hanquyou® (rituximab®), the first domestic biosimilar in China and Europe (trastuzumab, EU trade name: Zercepac®), and comprehensively promoted tumor immunotherapy based on its own anti-PD-1 monoclonal antibody HLX10.
Today, Fuhong Hanlin has successfully grown from an R&D team of the first two to an international biopharmaceutical company with nearly 2,000 people, with more than 100 returnees from overseas, and has continued to improve team building. Over the past year, inspired by the company's mission and vision, many outstanding talents who have been responsible for drug development and production, quality technology, and commercial operations in top international biopharmaceutical companies have joined Fuhong Hanlin, including Ms. Huang Wei, senior vice president of production and engineering, Dr. Xu Shengchang, senior vice president of technical operations, Mr. Yu Cheng, vice president of marketing and commercial operations, Mr. Zeng Zuyun, vice president of sales, and Dr. Liu Ningshu, who recently joined the company.